Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Genie29jon Mar 02, 2023 8:24pm
218 Views
Post# 35316499

And here we are…

And here we are…

I have mixed feelings about this weeks Replicel meeting

1. I think Andrew has ambitions but was dealt a losing hand. Serious props if he can kick things into higher gear

2. what an absolute disappointment the AGM call was. I was shocked...like seriously shocked. I was fully expecting more with the device. The message for the last several years (and the same with this week) was "a few more tweaks and we will be there". My gawd, how much more of this can happen? I feel like this device is about 100 years in the making. 

my gut is telling me this company is now 100% dependent on Shiseido and a positive outcome. 

To know they have ANOTHER YEAR to get a 510k submission is terrifying. I hope they get proper funding bc I sadly think this is nearing the end of its journey which would such such a bummer 

still staying cautiously optimistic, but barely 

<< Previous
Bullboard Posts
Next >>